BIOGEN EXEC SAYS ROLLING SUBMISSION FOR ACCELERATED APPROVAL OF SECOND ALZHEIMER'S DRUG LECANEMAB ONGOING, EXPECTED TO BE COMPLETED IN H1 2022- JPM CONF
Biogen Exec Says Rolling Submission For Accelerated Approval Of Second Alzheimer's Drug Lecanemab Ongoing, Expected To Be Completed In H1 2022- Jpm Conf
January 10, 2022 at 09:58 am EST
Share
Share
